GSK Acquires IDRx to Strengthen Cancer Portfolio

FTSE 100-listed GlaxoSmithKline PLC (GB:GSK) announced its agreement to acquire U.S.-based IDRx, Inc. in a move to strengthen its gastrointestinal (GI) cancer portfolio. GSK will pay up to $1.15 billion for the acquisition, including a $1 billion upfront payment and an additional $150 million tied to regulatory approval milestones. Following the news, GSK shares fell by 0.63% as of writing.

Bạn đang xem: GSK Acquires IDRx to Strengthen Cancer Portfolio

Based in the UK, GlaxoSmithKline is a global pharmaceutical company with a presence in roughly 80 countries. Meanwhile, IDRx is a clinical-stage company focused on developing targeted cancer treatments.

GSK Expands Gastrointestinal Cancer Pipeline

Xem thêm : Couple with long-COVID ask how to manage $2 million portfolio

With this deal, GSK has expanded its portfolio with a treatment of rare gastrointestinal tumours. The acquisition includes IDRX-42, which treats gastrointestinal stromal tumours (GIST). According to GSK’s update, the U.S. Food and Drug Administration (FDA) has awarded IDRX-42 fast track status for treating GIST patients who experience disease progression or intolerance to imatinib.

The current treatments for GIST are often ineffective due to new KIT mutations after first-line treatment, resulting in relapse. However, IDRX-42 has shown effectiveness against all major primary and secondary KIT mutations, aiming to enhance treatment outcomes. Meanwhile, IDRX-42 is also easier for patients to tolerate as compared to current treatments. With its broad mutational coverage and high selectivity, which may enhance tolerance, IDRX-42 has the potential to become a leading treatment in its class.

Notably, KIT mutations are genetic alterations in the KIT gene, linked to the development of various types of cancer.

Xem thêm : Investing Moves to Make at the Start of the Year

In recent years, GSK has ramped up its focus on cancer treatments in response to challenges in its vaccines division. This acquisition reflects GSK’s strategy of identifying and developing promising treatments that target specific cancer-related mechanisms. Moreover, the deal is aligned with GSK’s long-term growth plan, aimed at enhancing its portfolio of medicines through 2031 and beyond.

Is GSK a Good Stock to Buy?

According to the consensus on TipRanks, GSK stock has received a Hold rating backed by seven Hold, two Buy, and two Sell recommendations. The GSK share price forecast is set at 1,617.5p, projecting an increase of 21% from the current level.

See more GSK analyst ratings

Disclosure